Liu Pharmaceutical Group (603368.SH): Plans to add about 100 new stores throughout the year
Gelonghui, April 30, 丨 Liuyao Group (603368.SH) said at an investor exchange meeting that the company's retail sector will further improve the store layout in 2024, plan to add about 100 new stores throughout the year, continue to optimize variety management, maintain the advantages of differentiated varieties, increase the sales share of core strategic varieties, self-produced Chinese herbal medicine tablets, etc. in stores, and optimize the variety structure. In addition, continue to develop specialized services such as chronic disease management, implement digital health services such as smart patient education and AI consultation as soon as possible, give full play to the advantages of self-built Internet hospitals, and carry out prescription outreach projects to form “Medical+Pharmaceutical+
Liu Pharmaceutical Group (603368.SH): At present, the company has cooperated with more than 30 core medical institutions in Guangxi on SPD projects
Gelonghui, April 30丨Liuyao Group (603368.SH) said at an investor exchange meeting that in the first quarter of 2024, the company will use the advantages of pharmaceutical device collaboration and batch zero collaboration to accelerate the introduction and promotion of innovative drugs, continue to deepen the market penetration, and actively carry out SPD projects for hospital equipment and consumables to increase the market share of equipment consumables. Currently, the company has cooperated with more than 30 core medical institutions in Guangxi on SPD projects. The aging population and the increase in residents' ability to pay for medical care lay the foundation for future growth in the pharmaceutical market. In the current situation where the medical device consumables market is still scattered, small, and numerous, the company's medical treatment in Guangxi
SDIC Securities released a research report on April 28 stating that it gave Liuyao Group (603368.SH) a purchase rating, and the target price was 28.32 yuan. The main reasons for the rating include: 1) Incident: The company released its 2023 annual report
SDIC Securities released a research report on April 28 stating that it gave Liuyao Group (603368.SH) a purchase rating, and the target price was 28.32 yuan. The main reasons for the rating include: 1) Incident: The company released its 2023 annual report and 2024 quarterly report to achieve continuous steady growth in performance; 2) the overall cost ratio remained stable, and gross margin and net margin increased. (Mainichi Keizai Shimbun)
Liuyao Group (603368): Steady growth in wholesale business and accelerated retail and industrial layout are expected to open up room for growth
Event: The company released its 2023 annual report and 2024 quarterly report, and achieved steady growth in performance. In 2023, the company achieved operating income of 20.812 billion yuan, a year-on-year increase of 9.23%, and a net profit of 8.50 yuan to mother
Liuyao Group: The conversion price of “Liuyao Bonds to Bonds” was adjusted from 22.89 yuan/share to 22.53 yuan/share
Guangxi Liuyao Group Co., Ltd. announced that the conversion price of “Liuyao Bonds Transfer” was adjusted from 22.89 yuan/share to 22.53 yuan/share. The implementation date of this conversion price adjustment is April 30, 2024.
Liu Pharmaceutical Group (603368): High growth in the industrial sector and continuous improvement in profits in 23 years
1Q24 net profit grew steadily, and profitability continued to improve the company's operating income/net profit attributable to mother/net profit after deducting non-return to mother of 208.12/8.50/837 million yuan, +9.2%/+21.1%/
Express News | Liuyao Group: Net profit from mother in the first quarter was 300 million yuan, up 15.04% year-on-year
Estimating The Intrinsic Value Of Guangxi LiuYao Group Co., Ltd (SHSE:603368)
Key Insights Guangxi LiuYao Group's estimated fair value is CN¥21.40 based on 2 Stage Free Cash Flow to Equity Guangxi LiuYao Group's CN¥21.18 share price indicates it is trading at similar levels a
Express News | The first batch of fund annual reports is out! 10 billion manager's hidden heavy stock holdings revealed
Liuyao Group (603368): High net profit growth in 4Q23 is in line with equity incentive targets
4Q23 net profit grew rapidly. The annual results were in line with equity incentive targets. The company issued a quick 2023 performance report, and achieved operating income/net profit attributable to mother/net profit deducted from non-mother 208.12/8.47/8 in 2023.
Liu Pharmaceutical Group (603368.SH): Net profit increased 20.7% year-on-year in 2023
Gelonghui, March 19丨Liuyao Group (603368.SH) announced its 2023 annual results report. During the reporting period, the company achieved total operating revenue of 208,011.9029 million yuan, an increase of 9.23% over the previous year; net profit attributable to shareholders of listed companies was 8467.639 million yuan, an increase of 20.70% over the previous year. In the pharmaceutical wholesale sector, the company strengthens supplier cooperation, seizes high-quality new products, actively expands SPD projects for pharmaceutical consumables, promotes the implementation of the collection and distribution model, and steadily increases the size of the wholesale market, especially the market share of equipment consumables. In the pharmaceutical retail sector, the company continues to expand to zero
Liu Pharmaceutical Group (603368): Guangxi Pharmaceutical Wholesale Leader Diversified Development of Retail Industry Shapes Second Growth Curve
Core logic: As of 2024/2/27, the company's PE-TTM valuation is only 8.65 times (average PE value 11 times in the past 5 years, 10 times valuation in the past 3 years). The valuation is at a historically low level and has a strong margin of safety
Liu Pharmaceutical Group (603368): Leading regional pharmaceutical distribution, pharmaceutical industry leading cross-regional development
Flexible system+excellent management to build a regional pharmaceutical distribution leader in Guangxi. The predecessor of Liuyao Group was the Liuzhou Pharmaceutical Wholesale Station established in 1953. It was restructured into a private enterprise in 2002. Under the leadership of a flexible system and excellent management, it has been cultivated for a long time
Investors Aren't Buying Guangxi LiuYao Group Co., Ltd's (SHSE:603368) Earnings
With a price-to-earnings (or "P/E") ratio of 8.6x Guangxi LiuYao Group Co., Ltd (SHSE:603368) may be sending very bullish signals at the moment, given that almost half of all companies in China have P
Retail Investors Who Hold 42% of Guangxi LiuYao Group Co., Ltd (SHSE:603368) Gained 6.7%, Insiders Profited as Well
Key Insights The considerable ownership by retail investors in Guangxi LiuYao Group indicates that they collectively have a greater say in management and business strategy 50% of the business is hel
Express News | Liu Yao Group: Vice President Chen Hong resigns and Liang Zhen takes over
These 4 Measures Indicate That Guangxi LiuYao Group (SHSE:603368) Is Using Debt Reasonably Well
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will
Analysis of the investment value of Liu Yao's debt conversion: the industrial sector is rapidly developing, and both original stock and debt conversion valuations are low
Liu Yao Bond Transfer (113563.SH) Overview: AA grade, with a bond balance of 802 million yuan, accounting for 100% of the total issuance amount, with a remaining term of 2.05 years. The latest closing price was 117.68 yuan, and the conversion premium rate was 42.38
Liuyao Group (603368.SH): There is a business partnership with Daxanlin
Gelonghui, December 14|Liuyao Group (603368.SH) said on an interactive platform that the company has business cooperation with Daxanlin.
Changes in A-shares丨Liuyao Group rose nearly 8% and the proposed increase of not more than 1 billion yuan was approved
Gelonghui, December 11 | Liuyao Group (603368.SH) rose nearly 8% to 21.66 yuan, with a total market value of 7.846 billion yuan. Liuyao Group announced that it has recently received the “Approval for Registration of Guangxi Liuyao Group Co., Ltd. to issue shares to specific targets” issued by the China Securities Regulatory Commission. The company plans to issue no more than 108,668,493 shares (including capital) to no more than 35 specific targets that meet the requirements stipulated by the China Securities Regulatory Commission, and raise no more than 1 billion yuan in total capital, which will be used in traditional Chinese medicine formula granules for hospital equipment and consumables SPD projects and health industrial park projects.
No Data